Coral Gables, FL-based Catalyst Pharmaceuticals , Inc. (NASDAQ:CPRX), a $2.69 billion market cap biopharmaceutical company that has delivered an impressive 54% return to shareholders over the past ...
CORAL GABLES, Fla. - Catalyst Pharmaceuticals Inc. (NASDAQ:CPRX), a pharmaceutical company demonstrating excellent financial ...
For Full Prescribing and Safety Information for FIRDAPSE, please visit www.firdapse.com.
Catalyst Pharmaceuticals (CPRX) reported that its sub-licensee in Japan, DyDo Pharma has launched FIRDAPSE Tablets 10 mg in Japan for the ...
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) recently disclosed in an 8-K filing with the Securities and Exchange Commission on January 13, 2025, that the company has posted a corporate presentation ...
StockNews.com downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) from a strong-buy rating to a buy rating in a research note issued to investors on Saturday. CPRX has been the ...
This partnership will create a new company named Catalyst Brands. Analysts said the combination of these clothing stores will likely benefit from cross-marketing, cost reduction, and talent sharing.
Catalyst Pharmaceuticals’ controversial $375,000 rare autoimmune disease drug now won’t face generic competition from Teva until Feb. 25, 2035, thanks to a ...
It wasn't just fact-checking that Meta scrapped from its platforms as it prepares for the second Trump administration. The social media giant has also loosened its rules around hate speech and ...
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback